

## Researcher Elaine DeLack

### List of Research References

1. Launay JM, Ferrari P, Haimart M, Bursztejn C, Tabuteau F, Braconnier A, Pasques-Bondoux D, Luong C, & Dreux C. (1988). Serotonin metabolism and other biochemical parameters in infantile autism. A controlled study of 22 autistic children. Neuropsychobiology 20(1), pp. 1-11.
2. Lake CR, Ziegler MG, & Murphy DL. (1977, May). Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch Gen Psychiatry 34(5), pp. 553-556.
3. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, & Jernej B. (2007, Nov). Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord 37(10), pp. 1934-1940.
4. Gillberg C & Svennerholm L. (1987, July). CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 151, pp. 89-94.
5. Jergensen HS. (2007, Nov). Studies on the neuroendocrine role of serotonin. Dan Med Bull 54(4), pp. 266-288.
6. Ma Z, Zhang G, Jenney C, Krishnamoorthy S, & Tao R. (2008, July 7). Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. Eur J Pharmacology 588(2-3), pp. 198-206.
7. Larsson L.G., Renyi L., Ross S.B., Svensson B., Angeby-Moller K. (1990, Feb). Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT. Neuropharmacology, 29(2), pp. 86-91.
8. Baumann P.A. & Waldmeier P.C., (1984, January). Negative feedback control of serotonin release in vivo: comparison of 5-hydroxyindolacetic acid levels measured by voltammetry in conscious rats and by biochemical techniques. Neuroscience, 11(1), pp. 195-204.
9. Jabbi, M., Korf, J., Kema, I.P., Hartman, C., van der Pompe, G., Minderaa, R.B., Ormel, J., & den Boer, J.A. (2007, May). Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Mol Psychiatry, 12(5), pp. 483-490.

10. Curin JM, Terzic` IM, Petkovic` ZB, Zekan L, Terzic` IM, & Susnjara IM. (2003, August). Lower cortisol and higher ACTH levels in individuals with autism. J Autism Dev Disord 33(4), pp. 443-448.
11. Marinovic`-Curin J, Marinovic`-Terzic` I, Bujas-Petkovic` Z, Zekan L, Skrabic` V, Dogas Z, & Terzic` J. ((2008, Feb). Slower cortisol response during ACTH stimulation test in autistic children. Eur Child Adolesc Psychiatry 17(1), pp. 39-43.
12. Popova NK, Masiova LN, Morosova EA, Bulygina VV, & Seif I. (2006, Feb). MAO-A knockout attenuates adrenocortical response to various kinds of stress. Psychoneuroendocrinology 31(2), pp. 179-186.
13. Brummett BH, Boyle SH, Siegler IC, Kuhn CM, Surwit RS, Garrett ME, Collins A, Ashley-Koch A, & Williams RB. (2008, Oct). HPA axis function in male caregivers: effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR). Biol Psychol 79(2), pp. 250-255.
14. Hoshino Y, Yokoyama F, Watanabe M, Murata S, Kaneko M, Y Kumashiro H. (1987, June). The diurnal variation and response to dexamethasone suppression test of saliva cortisol level in autistic children. Jpn J Psychiatry Neurol 41(2), pp. 227-235.
15. Jergensen H, Knigge U, Kjaer A, Moller M, & Warberg J. (2002, Oct). Serotonergic stimulation of corticotropin-releasing hormone and proopiomelanocortin gene expression. J Neuroendocrinology 14(10), pp. 788-795.
16. Sandman CA, Touchette P, Marion S, Lenjavi M, & Chicz-Demet A. (2002, Oct 15). Disregulation of proopiomelanocortin and contagious maladaptive behavior. Regul Pept 108(2-3), pp. 179-185.
17. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A, & Spivak B. (2005, May). Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacology 15(3), pp. 305-309.
18. Dharia, S., & Parker, CR. Jr. (2004, November). Adrenal androgens and aging. Seminar on Reproduction Medicine, 22 (4), pp 361-8.
19. Harper, AJ., Buster, JE., & Casson, PR.(1999). Changes in adrenocortical function with aging and therapeutic implications. Seminar on Reproduction Endocrinology, 17 (4), pp. 327-38.

20. Craig IW. (2005). The role of monoamine oxidase A, MAOA, in the aetiology of antisocial behaviour: the importance of gene-environment interactions. Novartis Found Symp 268, pp. 227-237.
21. Cohen IL, Liu X, Schutz C, White BN, Jenkins EC, Brown WT, & Holden JJ. (2003, Sept). Association of autism severity with a monoamine oxidase A functional polymorphism. Clin Genet 64(3), pp. 190-197.
22. Davis LK, Hazlett HC, Librant AL, Nopoulos P, Sheffield VC, Piven J, & Wassink TH. (2008, Oct 5). Cortical enlargement in autism is associated with a functional VNTR in the monoamine oxidase A gene. Am J Med Genet B Neuropsychiatr Genet 1478(7), pp. 1145-1151.
23. Courchesne E, Carper R, & Akshoomoff N. (2003, Jul 16). Evidence of brain overgrowth in the first year of life in autism. JAMA 290(3), pp. 337-344.
24. Contini V, Marques FZ, Garcia CE, Hutz MH, & Bau CH. (2006, Apr 5). MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence. Am J Med Genet B Neuropsychiatry Genet 141B(3), pp. 305-308.
25. Dziobek I, Gold SM, Wolf OT, & Convit A. (2007, Jan 15). Hypercholesteremia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety. Psychiatry Res 149(1-3), pp. 321-324.
26. Brummett BH, Boyle SH, Siegler IC, Zuchner S, Ashley-Koch A, & Williams RB. (2008, Feb). Lipid levels are associated with a regulatory polymorphism of the monoamine oxidase-A gene promoter (MAOA-uVNTR). Med Sci Monit 14(2), pp. 57-61.
27. Heron P, Cousins K, Boyd C, & Daya S. (2001, Feb 23). Paradoxical effects of copper and manganese on brain mitochondrial function. Life-Sci 68(14), pp. 1575-1583.
28. Cakala M, Drabik J, Kaz`mierczak A, Kopczuk D, & Adamczyk A. (2006). Inhibition of mitochondrial complex II affects dopamine metabolism and decreases its uptake into striatal synaptosomes. Folia Neuropathol 44(4), pp. 238-243.
29. McNamara IM, Borelia AW, Bialowas LA, & Whitaker-Azmitia PM. (2008, Jan 16). Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res 1189, pp. 203-214.

- 30.** Youdim M.B.H. & Sandler M. (1968). Activation of monoamine oxidase and inhibition of aldehyde dehydrogenase by reserpine. European Journal of Pharmacology, 4, pp. 105 –108.
- 31.** Vijayalakshmi V, Lele JV, & Dagainawala HF. (1978). Effect of reserpine on the monoamine oxidase (MAO) activity in rat liver and brain. Biochemical Pharmacology 27(15), pp. 1985-1986.